BICYCLE THERAPEUTICS PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.4 USD | -0.39% |
|
+9.42% | +34.96% |
Financials (USD)
| Sales 2024 * | 27.96M | Sales 2025 * | 27.8M | Capitalization | 1.05B |
|---|---|---|---|---|---|
| Net income 2024 * | -228M | Net income 2025 * | -265M | EV / Sales 2024 * | 26.3 x |
| Net cash position 2024 * | 311M | Net cash position 2025 * | 229M | EV / Sales 2025 * | 29.4 x |
| P/E ratio 2024 * |
-4.62
x | P/E ratio 2025 * |
-4.38
x | Employees | 284 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 11.44% |
More Fundamentals
* Assessed data
More news
Latest transcript on Bicycle Therapeutics plc
More recommendations
More press releases
| 1 day | -0.39% | ||
| 1 week | +9.42% | ||
| Current month | -2.01% | ||
| 1 month | -0.61% | ||
| 3 months | +37.46% | ||
| 6 months | +41.78% | ||
| Current year | +34.96% |
1 week
21.61
24.96
1 month
21.6126.00
Current year
16.1327.24
1 year
12.5428.91
3 years
12.0862.08
5 years
6.2462.08
10 years
6.2462.08
| Managers | Title | Age | Since |
|---|---|---|---|
Kevin Lee
CEO | Chief Executive Officer | 55 | 15-08-31 |
Alethia Young
DFI | Director of Finance/CFO | 45 | 23-07-16 |
Alistair Milnes
COO | Chief Operating Officer | 50 | 20-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Pierre Legault
CHM | Chairman | 63 | 19-03-17 |
| Director/Board Member | 61 | 21-03-16 | |
Richard Kender
BRD | Director/Board Member | 68 | 19-07-23 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.06% | 0 M€ | 0.00% | - | |
| 0.05% | 0 M€ | 0.00% | - | |
| 0.03% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 24.4 | -0.37% | 66 681 |
| 24-04-18 | 24.49 | +12.24% | 698,554 |
| 24-04-17 | 21.82 | -0.50% | 718,891 |
| 24-04-16 | 21.93 | +0.50% | 153,221 |
| 24-04-15 | 21.82 | -2.15% | 253,610 |
Delayed Quote Nasdaq, April 19, 2024 at 11:33 am EDT
More quotes
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a class of medicines, which it refers to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Its product candidates BT5528, BT8009 and BT1718, are each a Bicycle Toxin Conjugate (BTC). BT5528 is a second-generation BTC designed to target Ephrin type A receptor 2 (EphA2). BT8009 is a second-generation BTC designed to target Nectin-4, a validated tumor antigen. BT1718 is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase (MT1 MMP). Its product candidates BT7480 and BT7455, are each a Bicycle tumor-targeted immune cell agonist (TICA). The Company is also focused on additional therapeutic areas other than its wholly owned oncology portfolio.
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
24.49
USD
Average target price
43.99
USD
Spread / Average Target
+79.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +34.96% | 1.05B | |
| -2.90% | 102B | |
| +1.54% | 96.07B | |
| -1.80% | 21.66B | |
| -17.95% | 20.77B | |
| -6.91% | 18.53B | |
| -40.31% | 16.91B | |
| -28.07% | 13.79B | |
| +0.19% | 13.33B | |
| +19.76% | 10.94B |
- Stock Market
- Equities
- BCYC Stock
